Afshari, A.R.; Jalili-Nik, M.; Soukhtanloo, M.; Ghorbani, A.; Sadeghnia, H.R.; Mollazadeh, H.; Karimi Roshan, M.; Rahmani, F.; Sabri, H.; Vahedi, M.M.; Mousavi, S.H. Auraptene-induced cytotoxicity mechanisms in human malignant glioblastoma (U87) cells: role of reactive oxygen species (ROS). EXCLI J., 2019, 18, 576-590.
[PMID: 31611741]

Chinot, O.L.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Carpentier, A.F.; Hoang-Xuan, K.; Kavan, P.; Cernea, D.; Brandes, A.A.; Hilton, M.; Abrey, L.; Cloughesy, T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med., 2014, 370(8), 709-722.
[http://dx.doi.org/10.1056/NEJMoa1308345] [PMID: 24552318]

Barbagallo, G.M.; Jenkinson, M.D.; Brodbelt, A.R. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br. J. Neurosurg., 2008, 22(3), 452-455.
[http://dx.doi.org/10.1080/02688690802182256] [PMID: 18568742]

Hou, L.C.; Veeravagu, A.; Hsu, A.R.; Tse, V.C. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg. Focus, 2006, 20(4)E5
[http://dx.doi.org/10.3171/foc.2006.20.4.2] [PMID: 16709036]

Tavana, E.; Mollazadeh, H.; Mohtashami, E.; Modaresi, S.M.S.; Hosseini, A.; Sabri, H.; Soltani, A.; Javid, H.; Afshari, A.R.; Sahebkar, A. Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme. Biofactors, 2019.
[http://dx.doi.org/10.1002/biof.1605] [PMID: 31880372]

Afshari, A.R.; Mollazadeh, H.; Mohtashami, E.; Soltani, A.; Soukhtanloo, M.; Hosseini, A.; Jalili-Nik, M.; Vahedi, M.M.; Roshan, M.K.; Sahebkar, A. Protective role of natural products in glioblastoma multiforme: A focus on nitric oxide pathway. Curr. Med. Chem., 2020.
[http://dx.doi.org/10.2174/0929867327666200130104757] [PMID: 32000638]

Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., II; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25(30), 4722-4729.
[http://dx.doi.org/10.1200/JCO.2007.12.2440] [PMID: 17947719]

Martínez-Garcia, M.; Álvarez-Linera, J.; Carrato, C.; Ley, L.; Luque, R.; Maldonado, X.; Martínez-Aguillo, M.; Navarro, L.M.; Vaz-Salgado, M.A.; Gil-Gil, M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin. Transl. Oncol., 2018, 20(1), 22-28.
[http://dx.doi.org/10.1007/s12094-017-1763-6] [PMID: 29086250]

McCracken, D.J.; Celano, E.C.; Voloschin, A.D.; Read, W.L.; Olson, J.J. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. J. Neurooncol., 2016, 130(1), 193-201.
[http://dx.doi.org/10.1007/s11060-016-2234-6] [PMID: 27502784]

Zheng, S.; Alfaro-Munoz, K.; Wei, W.; Wang, X.; Wang, F.; Eterovic, A.K.; Shaw, K.R.M.; Meric-Bernstam, F.; Fuller, G.N.; Chen, K.; Verhaak, R.G.; Mills, G.B.; Yung, W.K.A.; Weathers, S.P.; de Groot, J.F. Prospective Clinical Sequencing of Adult Glioma. Mol. Cancer Ther., 2019, 18(5), 991-1000.
[http://dx.doi.org/10.1158/1535-7163.MCT-18-1122] [PMID: 30926639]

Preusser, M.; Lim, M.; Hafler, D.A.; Reardon, D.A.; Sampson, J.H. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol., 2015, 11(9), 504-514.
[http://dx.doi.org/10.1038/nrneurol.2015.139] [PMID: 26260659]

Paw, I.; Carpenter, R.C.; Watabe, K.; Debinski, W.; Lo, H-W. Mechanisms regulating glioma invasion. Cancer Lett., 2015, 362(1), 1-7.
[http://dx.doi.org/10.1016/j.canlet.2015.03.015] [PMID: 25796440]

Li, X.; Wu, C.; Chen, N.; Gu, H.; Yen, A.; Cao, L.; Wang, E.; Wang, L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget, 2016, 7(22), 33440-33450.
[http://dx.doi.org/10.18632/oncotarget.7961] [PMID: 26967052]

Srivastava, C; Gupta, Y; Irshad, K; Chattopadhaya, P; Sarkar, C; Suri, A 123P Curcumin downregulates FAT1 expression via NFkB in glioblastoma. Annals of Oncology, 2017, 28(suppl_10) , mdx657. 005.

Soukhtanloo, M.; Mohtashami, E.; Maghrouni, A.; Mollazadeh, H.; Mousavi, S.H.; Roshan, M.K.; Tabatabaeizadeh, S.A.; Hosseini, A.; Vahedi, M.M.; Jalili-Nik, M.; Afshari, A.R. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway. Pharmacol. Rep., 2020, 72(2), 285-295.
[http://dx.doi.org/10.1007/s43440-020-00081-7] [PMID: 32152926]

Chen, R.; Cohen, A.L.; Colman, H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr. Treat. Options Oncol., 2016, 17(8), 42.
[http://dx.doi.org/10.1007/s11864-016-0418-0] [PMID: 27334978]

Driehuis, E.; Spelier, S.; Beltrán Hernández, I.; de Bree, R.; M Willems, S. Clevers, H.; Oliveira, S. Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. J. Clin. Med., 2019, 8(11), 1880.
[http://dx.doi.org/10.3390/jcm8111880] [PMID: 31694307]

Binder, ZA; Thorne, AH; Bakas, S; Wileyto, EP; Bilello, M; Akbari, H Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development. Cancer cell., 2018, 34(1), 163-77. e7.
[http://dx.doi.org/10.1016/j.ccell.2018.06.006]

Felsberg, J.; Hentschel, B.; Kaulich, K.; Gramatzki, D.; Zacher, A.; Malzkorn, B.; Kamp, M.; Sabel, M.; Simon, M.; Westphal, M.; Schackert, G.; Tonn, J.C.; Pietsch, T.; von Deimling, A.; Loeffler, M.; Reifenberger, G.; Weller, M. German Glioma Network. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin. Cancer Res., 2017, 23(22), 6846-6855.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0890] [PMID: 28855349]

Faulkner, C.; Palmer, A.; Williams, H.; Wragg, C.; Haynes, H.R.; White, P.; DeSouza, R.M.; Williams, M.; Hopkins, K.; Kurian, K.M. EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. Br. J. Neurosurg., 2015, 29(1), 23-29.
[http://dx.doi.org/10.3109/02688697.2014.950631] [PMID: 25141189]

Park, S.Y.; Piao, Y.; Martinez-Ledesma, E.; Dong, J.; Khan, S.; Mittal, S. Targeting MEK in EGFR amplified glioma stem like cells induces differentiation; AACR, 2019.

Padfield, E.; Ellis, H.P.; Kurian, K.M. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front. Oncol., 2015, 5, 5.
[http://dx.doi.org/10.3389/fonc.2015.00005] [PMID: 25688333]

Reardon, D.A.; Groves, M.D.; Wen, P.Y.; Nabors, L.; Mikkelsen, T.; Rosenfeld, S.; Raizer, J.; Barriuso, J.; McLendon, R.E.; Suttle, A.B.; Ma, B.; Curtis, C.M.; Dar, M.M.; de Bono, J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin. Cancer Res., 2013, 19(4), 900-908.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1707] [PMID: 23363814]

Reardon, D.A.; Nabors, L.B.; Mason, W.P.; Perry, J.R.; Shapiro, W.; Kavan, P.; Mathieu, D.; Phuphanich, S.; Cseh, A.; Fu, Y.; Cong, J.; Wind, S.; Eisenstat, D.D. BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-oncol., 2015, 17(3), 430-439.
[PMID: 25140039]

Sepúlveda-Sánchez, J.M.; Vaz, M.Á.; Balañá, C.; Gil-Gil, M.; Reynés, G.; Gallego, Ó.; Martínez-García, M.; Vicente, E.; Quindós, M.; Luque, R.; Ramos, A.; Ruano, Y.; Pérez-Segura, P.; Benavides, M.; Sánchez-Gómez, P.; Hernández-Laín, A. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-oncol., 2017, 19(11), 1522-1531.
[http://dx.doi.org/10.1093/neuonc/nox105] [PMID: 28575464]

Sequist, L.V.; Piotrowska, Z.; Niederst, M.J.; Heist, R.S.; Digumarthy, S.; Shaw, A.T.; Engelman, J.A. Osimertinib responses after disease progression in patients who had been receiving rociletinib. JAMA Oncol., 2016, 2(4), 541-543.
[http://dx.doi.org/10.1001/jamaoncol.2015.5009] [PMID: 26720284]

Batchelor, T.T.; Gerstner, E.R.; Ye, X.; Desideri, S.; Duda, D.G.; Peereboom, D.; Lesser, G.J.; Chowdhary, S.; Wen, P.Y.; Grossman, S.; Supko, J.G. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-oncol., 2017, 19(4), 567-575.
[PMID: 27663390]

Odia, Y.; Sul, J.; Shih, J.H.; Kreisl, T.N.; Butman, J.A.; Iwamoto, F.M.; Fine, H.A. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol., 2016, 5(2), 59-67.
[http://dx.doi.org/10.2217/cns-2015-0010] [PMID: 26860632]

Nghiemphu, P.L.; Ebiana, V.A.; Wen, P.; Gilbert, M.; Abrey, L.E.; Lieberman, F.; DeAngelis, L.M.; Robins, H.I.; Yung, W.K.A.; Chang, S.; Drappatz, J.; Mehta, M.P.; Levin, V.A.; Aldape, K.; Dancey, J.E.; Wright, J.J.; Prados, M.; Kuhn, J.; Cloughesy, T.F. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J. Neurooncol., 2018, 136(1), 79-86.
[http://dx.doi.org/10.1007/s11060-017-2624-4] [PMID: 28988377]

Pitz, M.W.; Eisenhauer, E.A.; MacNeil, M.V.; Thiessen, B.; Easaw, J.C.; Macdonald, D.R.; Eisenstat, D.D.; Kakumanu, A.S.; Salim, M.; Chalchal, H.; Squire, J.; Tsao, M.S.; Kamel-Reid, S.; Banerji, S.; Tu, D.; Powers, J.; Hausman, D.F.; Mason, W.P. Phase II study of PX-866 in recurrent glioblastoma. Neuro-oncol., 2015, 17(9), 1270-1274.
[http://dx.doi.org/10.1093/neuonc/nou365] [PMID: 25605819]

Wen, P.Y.; Touat, M.; Alexander, B.M.; Mellinghoff, I.K.; Ramkissoon, S.; McCluskey, C.S.; Pelton, K.; Haidar, S.; Basu, S.S.; Gaffey, S.C.; Brown, L.E.; Martinez-Ledesma, J.E.; Wu, S.; Kim, J.; Wei, W.; Park, M.A.; Huse, J.T.; Kuhn, J.G.; Rinne, M.L.; Colman, H.; Agar, N.Y.R.; Omuro, A.M.; DeAngelis, L.M.; Gilbert, M.R.; de Groot, J.F.; Cloughesy, T.F.; Chi, A.S.; Roberts, T.M.; Zhao, J.J.; Lee, E.Q.; Nayak, L.; Heath, J.R.; Horky, L.L.; Batchelor, T.T.; Beroukhim, R.; Chang, S.M.; Ligon, A.H.; Dunn, I.F.; Koul, D.; Young, G.S.; Prados, M.D.; Reardon, D.A.; Yung, W.K.A.; Ligon, K.L. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: An open-label, multicenter, multi-arm, phase II trial. J. Clin. Oncol., 2019, 37(9), 741-750.
[http://dx.doi.org/10.1200/JCO.18.01207] [PMID: 30715997]

Karimi Roshan, M.; Soltani, A.; Soleimani, A.; Rezaie Kahkhaie, K.; Afshari, A.R.; Soukhtanloo, M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie, 2019, 165, 229-234.
[http://dx.doi.org/10.1016/j.biochi.2019.08.003] [PMID: 31401189]

Batsios, G.; Viswanath, P.; Subramani, E.; Najac, C.; Gillespie, A.M.; Santos, R.D.; Molloy, A.R.; Pieper, R.O.; Ronen, S.M. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci. Rep., 2019, 9(1), 10521.
[http://dx.doi.org/10.1038/s41598-019-47021-x] [PMID: 31324855]

Fan, Q.; Aksoy, O.; Wong, R.A.; Ilkhanizadeh, S.; Novotny, C.J.; Gustafson, W.C.; Truong, A.Y.; Cayanan, G.; Simonds, E.F.; Haas-Kogan, D.; Phillips, J.J.; Nicolaides, T.; Okaniwa, M.; Shokat, K.M.; Weiss, W.A. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell, 2017, 31(3), 424-435.
[http://dx.doi.org/10.1016/j.ccell.2017.01.014] [PMID: 28292440]

Wahl, M.; Chang, S.M.; Phillips, J.J.; Molinaro, A.M.; Costello, J.F.; Mazor, T. Probing the PI3K/mTOR Pathway in Gliomas: A Phase II Study of Everolimus for Recurrent Adult Low Grade Gliomas. Cancer, 2017, 123(23), 4631.
[http://dx.doi.org/10.1002/cncr.30909] [PMID: 28759109]

Chinnaiyan, P.; Won, M.; Wen, P.Y.; Rojiani, A.M.; Werner-Wasik, M.; Shih, H.A.; Ashby, L.S.; Michael Yu, H.H.; Stieber, V.W.; Malone, S.C.; Fiveash, J.B.; Mohile, N.A.; Ahluwalia, M.S.; Wendland, M.M.; Stella, P.J.; Kee, A.Y.; Mehta, M.P. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-oncol., 2018, 20(5), 666-673.
[http://dx.doi.org/10.1093/neuonc/nox209] [PMID: 29126203]

Chheda, M.G.; Wen, P.Y.; Hochberg, F.H.; Chi, A.S.; Drappatz, J.; Eichler, A.F.; Yang, D.; Beroukhim, R.; Norden, A.D.; Gerstner, E.R.; Betensky, R.A.; Batchelor, T.T. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J. Neurooncol., 2015, 121(3), 627-634.
[http://dx.doi.org/10.1007/s11060-014-1680-2] [PMID: 25503302]

Schiff, D.; Jaeckle, K.A.; Anderson, S.K.; Galanis, E.; Giannini, C.; Buckner, J.C.; Stella, P.; Flynn, P.J.; Erickson, B.J.; Schwerkoske, J.F.; Kaluza, V.; Twohy, E.; Dancey, J.; Wright, J.; Sarkaria, J.N. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer, 2018, 124(7), 1455-1463.
[http://dx.doi.org/10.1002/cncr.31219] [PMID: 29313954]

Wick, W.; Gorlia, T.; Bady, P.; Platten, M.; van den Bent, M.J.; Taphoorn, M.J.; Steuve, J.; Brandes, A.A.; Hamou, M.F.; Wick, A.; Kosch, M.; Weller, M.; Stupp, R.; Roth, P.; Golfinopoulos, V.; Frenel, J.S.; Campone, M.; Ricard, D.; Marosi, C.; Villa, S.; Weyerbrock, A.; Hopkins, K.; Homicsko, K.; Lhermitte, B.; Pesce, G.; Hegi, M.E. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin. Cancer Res., 2016, 22(19), 4797-4806.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-3153] [PMID: 27143690]

Wen, P.Y.; Omuro, A.; Ahluwalia, M.S.; Fathallah-Shaykh, H.M.; Mohile, N.; Lager, J.J.; Laird, A.D.; Tang, J.; Jiang, J.; Egile, C.; Cloughesy, T.F. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-oncol., 2015, 17(9), 1275-1283.
[http://dx.doi.org/10.1093/neuonc/nov083] [PMID: 26019185]

Wen, P.Y.; Cloughesy, T.F.; Olivero, A.; Lu, X.; Mueller, L.; Fernandez Coimbra, A. A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma; American Society of Clinical Oncology, 2016.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.2012]

Das, S.; Marsden, P.A. Angiogenesis in glioblastoma. N. Engl. J. Med., 2013, 369(16), 1561-1563.
[http://dx.doi.org/10.1056/NEJMcibr1309402] [PMID: 24131182]

Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci., 2007, 8(8), 610-622.
[http://dx.doi.org/10.1038/nrn2175] [PMID: 17643088]

Morbidelli, L.; Donnini, S.; Ziche, M. Therapeutic implications of the nitric oxide pathway in the angiogenesis of tumors and inflammatory-related disorders. Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders; Elsevier, 2019, pp. 65-91.
[http://dx.doi.org/10.1016/B978-0-12-816545-4.00004-9]

Keunen, O.; Johansson, M.; Oudin, A.; Sanzey, M.; Rahim, S.A.A.; Fack, F.; Thorsen, F.; Taxt, T.; Bartos, M.; Jirik, R.; Miletic, H.; Wang, J.; Stieber, D.; Stuhr, L.; Moen, I.; Rygh, C.B.; Bjerkvig, R.; Niclou, S.P. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. USA, 2011, 108(9), 3749-3754.
[http://dx.doi.org/10.1073/pnas.1014480108] [PMID: 21321221]

Moustakas, A.; Kreisl, T.N. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. OncoTargets Ther., 2010, 3, 27-38.
[PMID: 20616955 ]

Zhang, X.; Zhang, W.; Cao, W-D.; Cheng, G.; Zhang, Y-Q. Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp. Ther. Med., 2012, 3(1), 9-14.
[http://dx.doi.org/10.3892/etm.2011.367] [PMID: 22969836]

Brown, N.; McBain, C.; Nash, S.; Hopkins, K.; Sanghera, P.; Saran, F.; Phillips, M.; Dungey, F.; Clifton-Hadley, L.; Wanek, K.; Krell, D.; Jeffries, S.; Khan, I.; Smith, P.; Mulholland, P. Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. PLoS One, 2016, 11(5)e0156369
[http://dx.doi.org/10.1371/journal.pone.0156369] [PMID: 27232884]

Taylor, J.W.; Dietrich, J.; Gerstner, E.R.; Norden, A.D.; Rinne, M.L.; Cahill, D.P.; Stemmer-Rachamimov, A.; Wen, P.Y.; Betensky, R.A.; Giorgio, D.H.; Snodgrass, K.; Randall, A.E.; Batchelor, T.T.; Chi, A.S. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J. Neurooncol., 2015, 121(3), 557-563.
[http://dx.doi.org/10.1007/s11060-014-1667-z] [PMID: 25411098]

Schäfer, N.; Gielen, G.H.; Kebir, S.; Wieland, A.; Till, A.; Mack, F.; Schaub, C.; Tzaridis, T.; Reinartz, R.; Niessen, M.; Fimmers, R.; Simon, M.; Coch, C.; Fuhrmann, C.; Herrlinger, U.; Scheffler, B.; Glas, M. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J. Cancer Res. Clin. Oncol., 2016, 142(7), 1581-1589.
[http://dx.doi.org/10.1007/s00432-016-2161-0] [PMID: 27100354]

Wen, P.Y.; Drappatz, J.; de Groot, J.; Prados, M.D.; Reardon, D.A.; Schiff, D.; Chamberlain, M.; Mikkelsen, T.; Desjardins, A.; Holland, J.; Ping, J.; Weitzman, R.; Cloughesy, T.F. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-oncol., 2018, 20(2), 249-258.
[http://dx.doi.org/10.1093/neuonc/nox154] [PMID: 29016998]

Wang, L.; Liang, L.; Yang, T.; Qiao, Y.; Xia, Y.; Liu, L.; Li, C.; Lu, P.; Jiang, X. A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study. Medicine (Baltimore), 2017, 96(49)e9053
[http://dx.doi.org/10.1097/MD.0000000000009053] [PMID: 29245310]

Gerstner, E.R.; Ye, X.; Duda, D.G.; Levine, M.A.; Mikkelsen, T.; Kaley, T.J.; Olson, J.J.; Nabors, B.L.; Ahluwalia, M.S.; Wen, P.Y.; Jain, R.K.; Batchelor, T.T.; Grossman, S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-oncol., 2015, 17(10), 1386-1392.
[http://dx.doi.org/10.1093/neuonc/nov085] [PMID: 26008604]

Nabors, L.B.; Fink, K.L.; Mikkelsen, T.; Grujicic, D.; Tarnawski, R.; Nam, D.H.; Mazurkiewicz, M.; Salacz, M.; Ashby, L.; Zagonel, V.; Depenni, R.; Perry, J.R.; Hicking, C.; Picard, M.; Hegi, M.E.; Lhermitte, B.; Reardon, D.A. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-oncol., 2015, 17(5), 708-717.
[http://dx.doi.org/10.1093/neuonc/nou356] [PMID: 25762461]

Stupp, R.; Hegi, M.E.; Gorlia, T.; Erridge, S.C.; Perry, J.; Hong, Y-K.; Aldape, K.D.; Lhermitte, B.; Pietsch, T.; Grujicic, D.; Steinbach, J.P.; Wick, W.; Tarnawski, R.; Nam, D.H.; Hau, P.; Weyerbrock, A.; Taphoorn, M.J.; Shen, C.C.; Rao, N.; Thurzo, L.; Herrlinger, U.; Gupta, T.; Kortmann, R.D.; Adamska, K.; McBain, C.; Brandes, A.A.; Tonn, J.C.; Schnell, O.; Wiegel, T.; Kim, C.Y.; Nabors, L.B.; Reardon, D.A.; van den Bent, M.J.; Hicking, C.; Markivskyy, A.; Picard, M.; Weller, M. European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol., 2014, 15(10), 1100-1108.
[http://dx.doi.org/10.1016/S1470-2045(14)70379-1] [PMID: 25163906]

Lee, E.Q.; Kaley, T.J.; Duda, D.G.; Schiff, D.; Lassman, A.B.; Wong, E.T.; Mikkelsen, T.; Purow, B.W.; Muzikansky, A.; Ancukiewicz, M.; Huse, J.T.; Ramkissoon, S.; Drappatz, J.; Norden, A.D.; Beroukhim, R.; Weiss, S.E.; Alexander, B.M.; McCluskey, C.S.; Gerard, M.; Smith, K.H.; Jain, R.K.; Batchelor, T.T.; Ligon, K.L.; Wen, P.Y. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin. Cancer Res., 2015, 21(16), 3610-3618.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-3220] [PMID: 25910950]

Duerinck, J.; Du Four, S.; Sander, W.; Van Binst, A-M.; Everaert, H.; Michotte, A.; Hau, P.; Neyns, B. Sunitinib malate plus lomustine for patients with temozolomide-refractory recurrent anaplastic or low-grade glioma. Anticancer Res., 2015, 35(10), 5551-5557.
[PMID: 26408725]

Friedmann-Morvinski, D.; Narasimamurthy, R.; Xia, Y.; Myskiw, C.; Soda, Y.; Verma, I.M. Targeting NF-κB in glioblastoma: A therapeutic approach. Sci. Adv., 2016, 2(1)e1501292
[http://dx.doi.org/10.1126/sciadv.1501292] [PMID: 26824076]

Cahill, K.E.; Morshed, R.A.; Yamini, B. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. Neuro-oncol., 2016, 18(3), 329-339.
[http://dx.doi.org/10.1093/neuonc/nov265] [PMID: 26534766]

Bonavia, R.; Inda, M.M.; Vandenberg, S.; Cheng, S.Y.; Nagane, M.; Hadwiger, P.; Tan, P.; Sah, D.W.; Cavenee, W.K.; Furnari, F.B. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene, 2012, 31(36), 4054-4066.
[http://dx.doi.org/10.1038/onc.2011.563] [PMID: 22139077]

Qian, C.; Li, P.; Yan, W.; Shi, L.; Zhang, J.; Wang, Y.; Liu, H.; You, Y. Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl2 pathway. Mol. Med. Rep., 2015, 11(3), 1951-1955.
[http://dx.doi.org/10.3892/mmr.2014.2951] [PMID: 25405848]

Lan, F.; Yang, Y.; Han, J.; Wu, Q.; Yu, H.; Yue, X. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Int. J. Oncol., 2016, 48(2), 559-568.
[http://dx.doi.org/10.3892/ijo.2015.3271] [PMID: 26648123]

Kong, X-T; Nguyen, N; Choi, Y; Zhang, G; Nguyen, H; Filka, E Actr-53. Safety And Efficacy Evaluation Of A Phase Ii Study Of Bortezomib In Combination With Temozolomide And Regional Radiation Therapy For Upfront Treatment Of Patients With Newlydiagnosed Glioblastoma Multiforme (gbm). Neuro-Oncology, 2017, 19(suppl_6), vi12-vi.

Raizer, J.J.; Chandler, J.P.; Ferrarese, R.; Grimm, S.A.; Levy, R.M.; Muro, K.; Rosenow, J.; Helenowski, I.; Rademaker, A.; Paton, M.; Bredel, M. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J. Neurooncol., 2016, 129(1), 139-146.
[http://dx.doi.org/10.1007/s11060-016-2156-3] [PMID: 27300524]

Odia, Y.; Kreisl, T.N.; Aregawi, D.; Innis, E.K.; Fine, H.A. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J. Neurooncol., 2015, 125(1), 191-195.
[http://dx.doi.org/10.1007/s11060-015-1894-y] [PMID: 26285768]

Robe, P.A.; Bentires-Alj, M.; Bonif, M.; Rogister, B.; Deprez, M.; Haddada, H.; Khac, M.T.; Jolois, O.; Erkmen, K.; Merville, M.P.; Black, P.M.; Bours, V. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin. Cancer Res., 2004, 10(16), 5595-5603.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0392] [PMID: 15328202]

Robe, P.A.; Martin, D.H.; Nguyen-Khac, M.T.; Artesi, M.; Deprez, M.; Albert, A.; Vanbelle, S.; Califice, S.; Bredel, M.; Bours, V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer, 2009, 9(1), 372.
[http://dx.doi.org/10.1186/1471-2407-9-372] [PMID: 19840379]

Kanzawa, T.; Kondo, Y.; Ito, H.; Kondo, S.; Germano, I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res., 2003, 63(9), 2103-2108.
[PMID: 12727826]

Kumthekar, P.; Grimm, S.; Chandler, J.; Mehta, M.; Marymont, M.; Levy, R.; Muro, K.; Helenowski, I.; McCarthy, K.; Fountas, L.; Raizer, J. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. J. Neurooncol., 2017, 133(3), 589-594.
[http://dx.doi.org/10.1007/s11060-017-2469-x] [PMID: 28510787]

Brandes, A.A.; Bartolotti, M.; Tosoni, A.; Franceschi, E. Nitrosoureas in the management of malignant gliomas. Curr. Neurol. Neurosci. Rep., 2016, 16(2), 13.
[http://dx.doi.org/10.1007/s11910-015-0611-8] [PMID: 26750128]

Chang, S.; Zhang, P.; Cairncross, J.G.; Gilbert, M.R.; Bahary, J-P.; Dolinskas, C.A.; Chakravarti, A.; Aldape, K.D.; Bell, E.H.; Schiff, D.; Jaeckle, K.; Brown, P.D.; Barger, G.R.; Werner-Wasik, M.; Shih, H.; Brachman, D.; Penas-Prado, M.; Robins, H.I.; Belanger, K.; Schultz, C.; Hunter, G.; Mehta, M. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-oncol., 2017, 19(2), 252-258.
[PMID: 27994066]

Herrlinger, U.; Tzaridis, T.; Mack, F.; Steinbach, J.P.; Schlegel, U.; Sabel, M.; Hau, P.; Kortmann, R.D.; Krex, D.; Grauer, O.; Goldbrunner, R.; Schnell, O.; Bähr, O.; Uhl, M.; Seidel, C.; Tabatabai, G.; Kowalski, T.; Ringel, F.; Schmidt-Graf, F.; Suchorska, B.; Brehmer, S.; Weyerbrock, A.; Renovanz, M.; Bullinger, L.; Galldiks, N.; Vajkoczy, P.; Misch, M.; Vatter, H.; Stuplich, M.; Schäfer, N.; Kebir, S.; Weller, J.; Schaub, C.; Stummer, W.; Tonn, J.C.; Simon, M.; Keil, V.C.; Nelles, M.; Urbach, H.; Coenen, M.; Wick, W.; Weller, M.; Fimmers, R.; Schmid, M.; Hattingen, E.; Pietsch, T.; Coch, C.; Glas, M. Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet, 2019, 393(10172), 678-688.
[http://dx.doi.org/10.1016/S0140-6736(18)31791-4] [PMID: 30782343]

Mack, F.; Schäfer, N.; Kebir, S.; Stuplich, M.; Schaub, C.; Niessen, M.; Scheffler, B.; Herrlinger, U.; Glas, M. Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma. Oncology, 2014, 86(5-6), 369-372.
[http://dx.doi.org/10.1159/000360295] [PMID: 24942787]

Brandes, A.A.; Finocchiaro, G.; Zagonel, V.; Reni, M.; Caserta, C.; Fabi, A.; Clavarezza, M.; Maiello, E.; Eoli, M.; Lombardi, G.; Monteforte, M.; Proietti, E.; Agati, R.; Eusebi, V.; Franceschi, E. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-oncol., 2016, 18(9), 1304-1312.
[http://dx.doi.org/10.1093/neuonc/now035] [PMID: 26951379]

Wick, W.; Gorlia, T.; Bendszus, M.; Taphoorn, M.; Sahm, F.; Harting, I.; Brandes, A.A.; Taal, W.; Domont, J.; Idbaih, A.; Campone, M.; Clement, P.M.; Stupp, R.; Fabbro, M.; Le Rhun, E.; Dubois, F.; Weller, M.; von Deimling, A.; Golfinopoulos, V.; Bromberg, J.C.; Platten, M.; Klein, M.; van den Bent, M.J. Lomustine and bevacizumab in progressive glioblastoma. N. Engl. J. Med., 2017, 377(20), 1954-1963.
[http://dx.doi.org/10.1056/NEJMoa1707358] [PMID: 29141164]

Aoki, T; Arakawa, Y; Ueba, T; Oda, M; Nishida, N; Akiyama, Y Phase I/II study of temozolomide plus nimustine chemotherapy for recurrent malignant gliomas: Kyoto Neuro-oncology Group. Neurologia medico-chirurgica., 2016, oa. 2016-0162.

Chamberlain, M.C.; Colman, H.; Kim, B.T.; Raizer, J. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. J. Neurooncol., 2017, 131(3), 507-516.
[http://dx.doi.org/10.1007/s11060-016-2241-7] [PMID: 28204914]

Duerinck, J.; Du Four, S.; Bouttens, F.; Andre, C.; Verschaeve, V.; Van Fraeyenhove, F.; Chaskis, C.; D’Haene, N.; Le Mercier, M.; Rogiers, A.; Michotte, A.; Salmon, I.; Neyns, B. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. J. Neurooncol., 2018, 136(1), 115-125.
[http://dx.doi.org/10.1007/s11060-017-2629-z] [PMID: 28988341]

Weller, M.; Roth, P.; Preusser, M.; Wick, W.; Reardon, D.A.; Platten, M.; Sampson, J.H. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat. Rev. Neurol., 2017, 13(6), 363-374.
[http://dx.doi.org/10.1038/nrneurol.2017.64] [PMID: 28497804]

Lim, M.; Xia, Y.; Bettegowda, C.; Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol., 2018, 15(7), 422-442.
[http://dx.doi.org/10.1038/s41571-018-0003-5] [PMID: 29643471]

Zheng, Y.; Ma, Y.; Yue, H.; Liu, G.; Han, S. EGFRvIII epigenetically regulates ARHI to promote glioma cell proliferation and migration. Exp. Mol. Pathol., 2020.112104344
[http://dx.doi.org/10.1016/j.yexmp.2019.104344] [PMID: 31751560]

Westphal, M.; Heese, O.; Steinbach, J.P.; Schnell, O.; Schackert, G.; Mehdorn, M.; Schulz, D.; Simon, M.; Schlegel, U.; Senft, C.; Geletneky, K.; Braun, C.; Hartung, J.G.; Reuter, D.; Metz, M.W.; Bach, F.; Pietsch, T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur. J. Cancer, 2015, 51(4), 522-532.
[http://dx.doi.org/10.1016/j.ejca.2014.12.019] [PMID: 25616647]

Desjardins, A.; Randazzo, D.; Peters, K.B.; Johnson, M.O.; Massey, W.; Herndon, J.E. Actr-64. Phase 2 Study Of Sym004 For Adult Patients With Recurrent Glioblastoma (gbm). Neuro-oncol., 2017, 19(Suppl. 6), vi14.
[http://dx.doi.org/10.1093/neuonc/nox168.052]

Reardon, D.A.; Lassman, A.B.; van den Bent, M.; Kumthekar, P.; Merrell, R.; Scott, A.M.; Fichtel, L.; Sulman, E.P.; Gomez, E.; Fischer, J.; Lee, H.J.; Munasinghe, W.; Xiong, H.; Mandich, H.; Roberts-Rapp, L.; Ansell, P.; Holen, K.D.; Gan, H.K. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-oncol., 2017, 19(7), 965-975.
[PMID: 28039367]

Wang, Y.; Pan, L. Sheng Xf, Chen S, Dai Jz. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in C hinese patients. Asia Pac. J. Clin. Oncol., 2016, 12(1), e23-e9.
[http://dx.doi.org/10.1111/ajco.12166] [PMID: 24571331]

Yu, A.; Faiq, N.; Green, S.; Lai, A.; Green, R.; Hu, J.; Cloughesy, T.F.; Mellinghoff, I.; Nghiemphu, P.L. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J. Neurooncol., 2017, 134(2), 357-362.
[http://dx.doi.org/10.1007/s11060-017-2533-6] [PMID: 28669012]

Blaes, J.; Thomé, C.M.; Pfenning, P-N.; Rübmann, P.; Sahm, F.; Wick, A.; Bunse, T.; Schmenger, T.; Sykora, J.; von Deimling, A.; Wiestler, B.; Merz, C.; Jugold, M.; Haberkorn, U.; Abdollahi, A.; Debus, J.; Gieffers, C.; Kunz, C.; Bendszus, M.; Kluge, M.; Platten, M.; Fricke, H.; Wick, W.; Lemke, D. Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma. Mol. Cancer Res., 2018, 16(5), 767-776.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0563] [PMID: 29453321]

Wick, W.; Fricke, H.; Junge, K.; Kobyakov, G.; Martens, T.; Heese, O.; Wiestler, B.; Schliesser, M.G.; von Deimling, A.; Pichler, J.; Vetlova, E.; Harting, I.; Debus, J.; Hartmann, C.; Kunz, C.; Platten, M.; Bendszus, M.; Combs, S.E. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin. Cancer Res., 2014, 20(24), 6304-6313.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0951-T] [PMID: 25338498]

Ahn, B.J.; Pollack, I.F.; Okada, H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel), 2013, 5(4), 1379-1412.
[http://dx.doi.org/10.3390/cancers5041379] [PMID: 24202450]

Yeo, A.T.; Charest, A. Immune checkpoint blockade biology in mouse models of glioblastoma. J. Cell. Biochem., 2017, 118(9), 2516-2527.
[http://dx.doi.org/10.1002/jcb.25948] [PMID: 28230277]

Caccese, M.; Indraccolo, S.; Zagonel, V.; Lombardi, G. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Crit. Rev. Oncol. Hematol., 2019, 135, 128-134.
[http://dx.doi.org/10.1016/j.critrevonc.2018.12.002] [PMID: 30819441]

Zhang, X.; Zhu, S.; Li, T.; Liu, Y-J.; Chen, W.; Chen, J. Targeting immune checkpoints in malignant glioma. Oncotarget, 2017, 8(4), 7157-7174.
[http://dx.doi.org/10.18632/oncotarget.12702] [PMID: 27756892]

Tan, A.C.; Heimberger, A.B.; Khasraw, M. Immune checkpoint inhibitors in gliomas. Curr. Oncol. Rep., 2017, 19(4), 23.
[http://dx.doi.org/10.1007/s11912-017-0586-5] [PMID: 28303490]

Lakin, N.; Rulach, R.; Nowicki, S.; Kurian, K.M. Current advances in checkpoint inhibitors: lessons from non-central nervous system cancers and potential for glioblastoma. Front. Oncol., 2017, 7, 141.
[http://dx.doi.org/10.3389/fonc.2017.00141] [PMID: 28730140]

Zeng, J; See, AP; Phallen, J; Jackson, CM; Belcaid, Z; Ruzevick, J Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. International Journal of Radiation Oncology* Biology* Physics., 2013, 86(2), 343-9.
[http://dx.doi.org/10.1016/j.ijrobp.2012.12.025]

Nduom, E.K.; Wei, J.; Yaghi, N.K.; Huang, N.; Kong, L-Y.; Gabrusiewicz, K.; Ling, X.; Zhou, S.; Ivan, C.; Chen, J.Q.; Burks, J.K.; Fuller, G.N.; Calin, G.A.; Conrad, C.A.; Creasy, C.; Ritthipichai, K.; Radvanyi, L.; Heimberger, A.B. PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncol., 2016, 18(2), 195-205.
[http://dx.doi.org/10.1093/neuonc/nov172] [PMID: 26323609]

Lowther, D.E.; Goods, B.A.; Lucca, L.E.; Lerner, B.A.; Raddassi, K.; van Dijk, D.; Hernandez, A.L.; Duan, X.; Gunel, M.; Coric, V.; Krishnaswamy, S.; Love, J.C.; Hafler, D.A. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight, 2016, 1(5)e85935
[http://dx.doi.org/10.1172/jci.insight.85935] [PMID: 27182555]

Omuro, A.; Vlahovic, G.; Lim, M.; Sahebjam, S.; Baehring, J.; Cloughesy, T.; Voloschin, A.; Ramkissoon, S.H.; Ligon, K.L.; Latek, R.; Zwirtes, R.; Strauss, L.; Paliwal, P.; Harbison, C.T.; Reardon, D.A.; Sampson, J.H. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-oncol., 2018, 20(5), 674-686.
[http://dx.doi.org/10.1093/neuonc/nox208] [PMID: 29106665]

Reardon, D; Omuro, A; Brandes, A; Rieger, J; Wick, A; Sepulveda, J OS10. 3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-oncology, 2017, 19(suppl_3), iii21-iii.

Reardon, D.A.; Kaley, T.J.; Dietrich, J.; Lim, M.; Dunn, G.P.; Gan, H.K. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM); American Society of Clinical Oncology, 2016.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.TPS2080]

Sahebjam, S. Forsyth, P; Arrington, J; Jaglal, M; Tran, ND; Etame, AB ATIM-18. A phase I trial of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab in patients with recurrent high grade glioma (NCT02313272). Neurooncology., 2017, 19(suppl_6), pp. vi30-vi.

Wheeler, C.J.; Das, A.; Liu, G.; Yu, J.S.; Black, K.L. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res., 2004, 10(16), 5316-5326.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-0497] [PMID: 15328167]

Liau, L.M.; Prins, R.M.; Kiertscher, S.M.; Odesa, S.K.; Kremen, T.J.; Giovannone, A.J.; Lin, J.W.; Chute, D.J.; Mischel, P.S.; Cloughesy, T.F.; Roth, M.D. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res., 2005, 11(15), 5515-5525.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0464] [PMID: 16061868]

Huang, X.; Ginwala, R.; Karabudak, A.; Jain, P.; Philip, R. Targeted multi-epitope therapeutic vaccine for the treatment of invasive glioblastoma multiforme. J. Immunother. Cancer, 2015, 3(S2), 436.
[http://dx.doi.org/10.1186/2051-1426-3-S2-P436]

Srinivasan, V.M.; Ferguson, S.D.; Lee, S.; Weathers, S-P.; Kerrigan, B.C.P.; Heimberger, A.B. Tumor vaccines for malignant gliomas. Neurotherapeutics, 2017, 14(2), 345-357.
[http://dx.doi.org/10.1007/s13311-017-0522-2] [PMID: 28389997]

Schuster, J.; Lai, R.K.; Recht, L.D.; Reardon, D.A.; Paleologos, N.A.; Groves, M.D.; Mrugala, M.M.; Jensen, R.; Baehring, J.M.; Sloan, A.; Archer, G.E.; Bigner, D.D.; Cruickshank, S.; Green, J.A.; Keler, T.; Davis, T.A.; Heimberger, A.B.; Sampson, J.H. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-oncol., 2015, 17(6), 854-861.
[http://dx.doi.org/10.1093/neuonc/nou348] [PMID: 25586468]

Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; O’Rourke, D.M.; Tran, D.D.; Fink, K.L.; Nabors, L.B.; Li, G.; Bota, D.A.; Lukas, R.V.; Ashby, L.S.; Duic, J.P.; Mrugala, M.M.; Cruickshank, S.; Vitale, L.; He, Y.; Green, J.A.; Yellin, M.J.; Turner, C.D.; Keler, T.; Davis, T.A.; Sampson, J.H. ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin. Cancer Res., 2020, 26(7), 1586-1594.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-1140] [PMID: 32034072]

Elsamadicy, A.A.; Chongsathidkiet, P.; Desai, R.; Woroniecka, K.; Farber, S.H.; Fecci, P.E.; Sampson, J.H. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin. Biol. Ther., 2017, 17(4), 507-513.
[http://dx.doi.org/10.1080/14712598.2017.1299705] [PMID: 28274144]

Fenstermaker, R.A.; Ciesielski, M.J.; Qiu, J.; Yang, N.; Frank, C.L.; Lee, K.P.; Mechtler, L.R.; Belal, A.; Ahluwalia, M.S.; Hutson, A.D. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother., 2016, 65(11), 1339-1352.
[http://dx.doi.org/10.1007/s00262-016-1890-x] [PMID: 27576783]

Ahluwalia, M.S.; Reardon, D.A.; Abad, A.P.; Curry, W.T.; Wong, E.T.; Belal, A. SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update; American Society of Clinical Oncology, 2019.

Reardon, D; Nabors, B; Kumthekar, P; Badruddoja, M; Fink, K; Lieberman, F Atim-10. Phase 2 Trial Of Sl-701, A Novel Immunotherapy Comprised Of Synthetic Short Peptides Against Gbm Targets Il-13rα2, Epha2, And Survivin, In Adults With Second-line Recurrent Gbm. Neuro-Oncology, 2017, 19(suppl_6), vi28-vi.

Peereboom, D; Nabors, L; Kumthekar, P; Badruddoja, M; Fink, K; Lieberman, F 373O Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). Annals of Oncology., 2018, 29(suppl_8), mdy273-361.

Peereboom, D.M.; Nabors, L.B.; Kumthekar, P.; Badruddoja, M.A.; Fink, K.L.; Lieberman, F.S. Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival; American Society of Clinical Oncology, 2018.

Wick, W.; Dietrich, P-Y.; Kuttruff, S.; Hilf, N.; Frenzel, K.; Admon, A. GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma; American Society of Clinical Oncology, 2018.

Rampling, R.; Peoples, S.; Mulholland, P.J.; James, A.; Al-Salihi, O.; Twelves, C.J.; McBain, C.; Jefferies, S.; Jackson, A.; Stewart, W.; Lindner, J.; Kutscher, S.; Hilf, N.; McGuigan, L.; Peters, J.; Hill, K.; Schoor, O.; Singh-Jasuja, H.; Halford, S.E.; Ritchie, J.W. A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin. Cancer Res., 2016, 22(19), 4776-4785.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0506] [PMID: 27225692]

Vandenberk, L.; Garg, A.D.; Verschuere, T.; Koks, C.; Belmans, J.; Beullens, M.; Agostinis, P.; De Vleeschouwer, S.; Van Gool, S.W. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. OncoImmunology, 2015, 5(2)e1083669
[http://dx.doi.org/10.1080/2162402X.2015.1083669] [PMID: 27057467]

Ludewig, P.; Gallizioli, M.; Urra, X.; Behr, S.; Brait, V.H.; Gelderblom, M. Dendritic cells in brain diseases. Biochimica et Biophysica Acta (BBA)-. Molecular Basis of Disease., 2016, 1862(3), 352-367.
[http://dx.doi.org/10.1016/j.bbadis.2015.11.003]

Wen, P.Y.; Reardon, D.A.; Armstrong, T.S.; Phuphanich, S.; Aiken, R.D.; Landolfi, J.C.; Curry, W.T.; Zhu, J.J.; Glantz, M.; Peereboom, D.M.; Markert, J.M.; LaRocca, R.; O’Rourke, D.M.; Fink, K.; Kim, L.; Gruber, M.; Lesser, G.J.; Pan, E.; Kesari, S.; Muzikansky, A.; Pinilla, C.; Santos, R.G.; Yu, J.S. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin. Cancer Res., 2019, 25(19), 5799-5807.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-0261] [PMID: 31320597]

Inogés, S.; Tejada, S.; de Cerio, A.L-D.; Gállego Pérez-Larraya, J.; Espinós, J.; Idoate, M.A.; Domínguez, P.D.; de Eulate, R.G.; Aristu, J.; Bendandi, M.; Pastor, F.; Alonso, M.; Andreu, E.; Cardoso, F.P.; Valle, R.D. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J. Transl. Med., 2017, 15(1), 104.
[http://dx.doi.org/10.1186/s12967-017-1202-z] [PMID: 28499389]

Buchroithner, J.; Erhart, F.; Pichler, J.; Widhalm, G.; Preusser, M.; Stockhammer, G.; Nowosielski, M.; Iglseder, S.; Freyschlag, C.F.; Oberndorfer, S.; Bordihn, K.; von Campe, G.; Hoffermann, M.; Ruckser, R.; Rössler, K.; Spiegl-Kreinecker, S.; Fischer, M.B.; Czech, T.; Visus, C.; Krumpl, G.; Felzmann, T.; Marosi, C. Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. Cancers (Basel), 2018, 10(10), 372.
[http://dx.doi.org/10.3390/cancers10100372] [PMID: 30301187]

Keskin, D.B.; Anandappa, A.J.; Sun, J.; Tirosh, I.; Mathewson, N.D.; Li, S.; Oliveira, G.; Giobbie-Hurder, A.; Felt, K.; Gjini, E.; Shukla, S.A.; Hu, Z.; Li, L.; Le, P.M.; Allesøe, R.L.; Richman, A.R.; Kowalczyk, M.S.; Abdelrahman, S.; Geduldig, J.E.; Charbonneau, S.; Pelton, K.; Iorgulescu, J.B.; Elagina, L.; Zhang, W.; Olive, O.; McCluskey, C.; Olsen, L.R.; Stevens, J.; Lane, W.J.; Salazar, A.M.; Daley, H.; Wen, P.Y.; Chiocca, E.A.; Harden, M.; Lennon, N.J.; Gabriel, S.; Getz, G.; Lander, E.S.; Regev, A.; Ritz, J.; Neuberg, D.; Rodig, S.J.; Ligon, K.L.; Suvà, M.L.; Wucherpfennig, K.W.; Hacohen, N.; Fritsch, E.F.; Livak, K.J.; Ott, P.A.; Wu, C.J.; Reardon, D.A. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565(7738), 234-239.
[http://dx.doi.org/10.1038/s41586-018-0792-9] [PMID: 30568305]

Liau, L.M.; Ashkan, K.; Tran, D.D.; Campian, J.L.; Trusheim, J.E.; Cobbs, C.S.; Heth, J.A.; Salacz, M.; Taylor, S.; D’Andre, S.D.; Iwamoto, F.M.; Dropcho, E.J.; Moshel, Y.A.; Walter, K.A.; Pillainayagam, C.P.; Aiken, R.; Chaudhary, R.; Goldlust, S.A.; Bota, D.A.; Duic, P.; Grewal, J.; Elinzano, H.; Toms, S.A.; Lillehei, K.O.; Mikkelsen, T.; Walbert, T.; Abram, S.R.; Brenner, A.J.; Brem, S.; Ewend, M.G.; Khagi, S.; Portnow, J.; Kim, L.J.; Loudon, W.G.; Thompson, R.C.; Avigan, D.E.; Fink, K.L.; Geoffroy, F.J.; Lindhorst, S.; Lutzky, J.; Sloan, A.E.; Schackert, G.; Krex, D.; Meisel, H.J.; Wu, J.; Davis, R.P.; Duma, C.; Etame, A.B.; Mathieu, D.; Kesari, S.; Piccioni, D.; Westphal, M.; Baskin, D.S.; New, P.Z.; Lacroix, M.; May, S.A.; Pluard, T.J.; Tse, V.; Green, R.M.; Villano, J.L.; Pearlman, M.; Petrecca, K.; Schulder, M.; Taylor, L.P.; Maida, A.E.; Prins, R.M.; Cloughesy, T.F.; Mulholland, P.; Bosch, M.L. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med., 2018, 16(1), 142.
[http://dx.doi.org/10.1186/s12967-018-1507-6] [PMID: 29843811]

Bloch, O.; Lim, M.; Sughrue, M.E.; Komotar, R.J.; Abrahams, J.M.; O’Rourke, D.M.; D’Ambrosio, A.; Bruce, J.N.; Parsa, A.T. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin. Cancer Res., 2017, 23(14), 3575-3584.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1369] [PMID: 28193626]

Ji, N.; Zhang, Y.; Liu, Y.; Xie, J.; Wang, Y.; Hao, S.; Gao, Z. Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial. JCI Insight, 2018, 3(10), 99145.
[http://dx.doi.org/10.1172/jci.insight.99145] [PMID: 29769450]

Bloch, O.; Crane, C.A.; Fuks, Y.; Kaur, R.; Aghi, M.K.; Berger, M.S.; Butowski, N.A.; Chang, S.M.; Clarke, J.L.; McDermott, M.W.; Prados, M.D.; Sloan, A.E.; Bruce, J.N.; Parsa, A.T. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-oncol., 2014, 16(2), 274-279.
[http://dx.doi.org/10.1093/neuonc/not203] [PMID: 24335700]

Pellegatta, S.; Eoli, M.; Cuccarini, V.; Anghileri, E.; Pollo, B.; Pessina, S.; Frigerio, S.; Servida, M.; Cuppini, L.; Antozzi, C.; Cuzzubbo, S.; Corbetta, C.; Paterra, R.; Acerbi, F.; Ferroli, P.; DiMeco, F.; Fariselli, L.; Parati, E.A.; Bruzzone, M.G.; Finocchiaro, G. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. OncoImmunology, 2018, 7(4)e1412901
[http://dx.doi.org/10.1080/2162402X.2017.1412901] [PMID: 29632727]

Maus, M.V.; June, C.H. Making better chimeric antigen receptors for adoptive T-cell therapy; AACR, 2016.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1433]

Plautz, G.E.; Miller, D.W.; Barnett, G.H.; Stevens, G.H.; Maffett, S.; Kim, J.; Cohen, P.A.; Shu, S. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res., 2000, 6(6), 2209-2218.
[PMID: 10873070]

Kong, D-S.; Nam, D-H.; Kang, S-H.; Lee, J.W.; Chang, J-H.; Kim, J-H.; Lim, Y.J.; Koh, Y.C.; Chung, Y.G.; Kim, J.M.; Kim, C.H. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget, 2017, 8(4), 7003-7013.
[http://dx.doi.org/10.18632/oncotarget.12273] [PMID: 27690294]

Brown, C.E.; Alizadeh, D.; Starr, R.; Weng, L.; Wagner, J.R.; Naranjo, A.; Ostberg, J.R.; Blanchard, M.S.; Kilpatrick, J.; Simpson, J.; Kurien, A.; Priceman, S.J.; Wang, X.; Harshbarger, T.L.; D’Apuzzo, M.; Ressler, J.A.; Jensen, M.C.; Barish, M.E.; Chen, M.; Portnow, J.; Forman, S.J.; Badie, B. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med., 2016, 375(26), 2561-2569.
[http://dx.doi.org/10.1056/NEJMoa1610497] [PMID: 28029927]

Johnson, LA; Scholler, J; Ohkuri, T; Kosaka, A; Patel, PR; McGettigan, SE Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science translational medicine., 2015, 7(275), 275ra22-ra22.
[http://dx.doi.org/10.1126/scitranslmed.aaa4963]

Choi, B.D.; Suryadevara, C.M.; Gedeon, P.C.; Herndon, J.E., II; Sanchez-Perez, L.; Bigner, D.D.; Sampson, J.H. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J. Clin. Neurosci., 2014, 21(1), 189-190.
[http://dx.doi.org/10.1016/j.jocn.2013.03.012] [PMID: 24054399]

Brown, C.E.; Badie, B.; Barish, M.E.; Weng, L.; Ostberg, J.R.; Chang, W-C.; Naranjo, A.; Starr, R.; Wagner, J.; Wright, C.; Zhai, Y.; Bading, J.R.; Ressler, J.A.; Portnow, J.; D’Apuzzo, M.; Forman, S.J.; Jensen, M.C. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res., 2015, 21(18), 4062-4072.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0428] [PMID: 26059190]

Kong, S.; Sengupta, S.; Tyler, B.; Bais, A.J.; Ma, Q.; Doucette, S.; Zhou, J.; Sahin, A.; Carter, B.S.; Brem, H.; Junghans, R.P.; Sampath, P. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin. Cancer Res., 2012, 18(21), 5949-5960.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0319] [PMID: 22966020]

O’Rourke, D.M.; Nasrallah, M.P.; Desai, A.; Melenhorst, J.J.; Mansfield, K.; Morrissette, J.J.D.; Martinez-Lage, M.; Brem, S.; Maloney, E.; Shen, A.; Isaacs, R.; Mohan, S.; Plesa, G.; Lacey, S.F.; Navenot, J.M.; Zheng, Z.; Levine, B.L.; Okada, H.; June, C.H.; Brogdon, J.L.; Maus, M.V. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med., 2017, 9(399)eaaa0984
[http://dx.doi.org/10.1126/scitranslmed.aaa0984] [PMID: 28724573]

Ahmed, N.; Brawley, V.; Hegde, M.; Bielamowicz, K.; Kalra, M.; Landi, D.; Robertson, C.; Gray, T.L.; Diouf, O.; Wakefield, A.; Ghazi, A.; Gerken, C.; Yi, Z.; Ashoori, A.; Wu, M.F.; Liu, H.; Rooney, C.; Dotti, G.; Gee, A.; Su, J.; Kew, Y.; Baskin, D.; Zhang, Y.J.; New, P.; Grilley, B.; Stojakovic, M.; Hicks, J.; Powell, S.Z.; Brenner, M.K.; Heslop, H.E.; Grossman, R.; Wels, W.S.; Gottschalk, S. Her2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol., 2017, 3(8), 1094-1101.
[http://dx.doi.org/10.1001/jamaoncol.2017.0184] [PMID: 28426845]

Ahmed, N.; Brawley, V.; Hegde, M.; Bielamowicz, K.; Wakefield, A.; Ghazi, A. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. J. Immunother. Cancer, 2015, 3(S2), O11.
[http://dx.doi.org/10.1186/2051-1426-3-S2-O11]

Russell, S.J.; Peng, K-W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol., 2012, 30(7), 658-670.
[http://dx.doi.org/10.1038/nbt.2287] [PMID: 22781695]

Wollmann, G.; Ozduman, K.; van den Pol, A.N. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J., 2012, 18(1), 69-81.
[http://dx.doi.org/10.1097/PPO.0b013e31824671c9] [PMID: 22290260]

Liu, T-C.; Galanis, E.; Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol., 2007, 4(2), 101-117.
[http://dx.doi.org/10.1038/ncponc0736] [PMID: 17259931]

Cloughesy, T.F.; Landolfi, J.; Vogelbaum, M.A.; Ostertag, D.; Elder, J.B.; Bloomfield, S.; Carter, B.; Chen, C.C.; Kalkanis, S.N.; Kesari, S.; Lai, A.; Lee, I.Y.; Liau, L.M.; Mikkelsen, T.; Nghiemphu, P.; Piccioni, D.; Accomando, W.; Diago, O.R.; Hogan, D.J.; Gammon, D.; Kasahara, N.; Kheoh, T.; Jolly, D.J.; Gruber, H.E.; Das, A.; Walbert, T. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-oncol., 2018, 20(10), 1383-1392.
[http://dx.doi.org/10.1093/neuonc/noy075] [PMID: 29762717]

Batich, K.A.; Reap, E.A.; Archer, G.E.; Sanchez-Perez, L.; Nair, S.K.; Schmittling, R.J.; Norberg, P.; Xie, W.; Herndon, J.E., II; Healy, P.; McLendon, R.E.; Friedman, A.H.; Friedman, H.S.; Bigner, D.; Vlahovic, G.; Mitchell, D.A.; Sampson, J.H. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin. Cancer Res., 2017, 23(8), 1898-1909.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2057] [PMID: 28411277]

Reap, E.A.; Suryadevara, C.M.; Batich, K.A.; Sanchez-Perez, L.; Archer, G.E.; Schmittling, R.J.; Norberg, P.K.; Herndon, J.E., II; Healy, P.; Congdon, K.L.; Gedeon, P.C.; Campbell, O.C.; Swartz, A.M.; Riccione, K.A.; Yi, J.S.; Hossain-Ibrahim, M.K.; Saraswathula, A.; Nair, S.K.; Dunn-Pirio, A.M.; Broome, T.M.; Weinhold, K.J.; Desjardins, A.; Vlahovic, G.; McLendon, R.E.; Friedman, A.H.; Friedman, H.S.; Bigner, D.D.; Fecci, P.E.; Mitchell, D.A.; Sampson, J.H. Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma. Cancer Res., 2018, 78(1), 256-264.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-0469] [PMID: 29093005]

Barrett, J.A.; Cai, H.; Miao, J.; Khare, P.D.; Gonzalez, P.; Dalsing-Hernandez, J.; Sharma, G.; Chan, T.; Cooper, L.J.N.; Lebel, F. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther., 2018, 25(5-6), 106-116.
[http://dx.doi.org/10.1038/s41417-018-0019-0] [PMID: 29755109]

Chiocca, E.A.; Nassiri, F.; Wang, J.; Peruzzi, P.; Zadeh, G. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? Neuro-oncol., 2019, 21(1), 14-25.
[http://dx.doi.org/10.1093/neuonc/noy170] [PMID: 30346600]

Robins, H.I.; Zhang, P.; Gilbert, M.R.; Chakravarti, A.; de Groot, J.F.; Grimm, S.A.; Wang, F.; Lieberman, F.S.; Krauze, A.; Trotti, A.M.; Mohile, N.; Kee, A.Y.; Colman, H.; Cavaliere, R.; Kesari, S.; Chmura, S.J.; Mehta, M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J. Neurooncol., 2016, 126(2), 309-316.
[http://dx.doi.org/10.1007/s11060-015-1966-z] [PMID: 26508094]

Lassen, U.; Chinot, O.L.; McBain, C.; Mau-Sørensen, M.; Larsen, V.A.; Barrie, M.; Roth, P.; Krieter, O.; Wang, K.; Habben, K.; Tessier, J.; Lahr, A.; Weller, M. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-oncol., 2015, 17(7), 1007-1015.
[http://dx.doi.org/10.1093/neuonc/nov019] [PMID: 25665807]

Lukas, R.V.; Rodon, J.; Becker, K.; Wong, E.T.; Shih, K.; Touat, M.; Fassò, M.; Osborne, S.; Molinero, L.; O’Hear, C.; Grossman, W.; Baehring, J. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol., 2018, 140(2), 317-328.
[http://dx.doi.org/10.1007/s11060-018-2955-9] [PMID: 30073642]

Holdhoff, M.; Ye, X.; Supko, J.G.; Nabors, L.B.; Desai, A.S.; Walbert, T.; Lesser, G.J.; Read, W.L.; Lieberman, F.S.; Lodge, M.A.; Leal, J.; Fisher, J.D.; Desideri, S.; Grossman, S.A.; Wahl, R.L.; Schiff, D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-oncol., 2017, 19(6), 845-852.
[http://dx.doi.org/10.1093/neuonc/nox020] [PMID: 28371832]

Galanis, E.; Anderson, S.K.; Miller, C.R.; Sarkaria, J.N.; Jaeckle, K.; Buckner, J.C.; Ligon, K.L.; Ballman, K.V.; Moore, D.F., Jr; Nebozhyn, M.; Loboda, A.; Schiff, D.; Ahluwalia, M.S.; Lee, E.Q.; Gerstner, E.R.; Lesser, G.J.; Prados, M.; Grossman, S.A.; Cerhan, J.; Giannini, C.; Wen, P.Y. Alliance for Clinical Trials in Oncology and ABTC. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-oncol., 2018, 20(4), 546-556.
[http://dx.doi.org/10.1093/neuonc/nox161] [PMID: 29016887]

Butowski, N.; Colman, H.; De Groot, J.F.; Omuro, A.M.; Nayak, L.; Wen, P.Y.; Cloughesy, T.F.; Marimuthu, A.; Haidar, S.; Perry, A.; Huse, J.; Phillips, J.; West, B.L.; Nolop, K.B.; Hsu, H.H.; Ligon, K.L.; Molinaro, A.M.; Prados, M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncol., 2016, 18(4), 557-564.
[http://dx.doi.org/10.1093/neuonc/nov245] [PMID: 26449250]